Hepatitis C is a very dangerous and difficult to treat disease. Therapy often lasts for many months, but no doctor can guarantee a final cure. That is why modern medicine is constantly in search of new and more effective means to combat this disease. High efficiency, in particular, is shown by courses of treatment using modern generics. After their use, many patients note a complete disappearance of signs of the disease.
Velpanat or “Epclusa” is one of the latest drugs to fight hepatitis C. It is a combination drug whose active ingredients are Velpatasvir and Sofosbuvir. The drug is prescribed only for adult patients, while its use leads to a complete cure, eliminating relapse. Perhaps use by people suffering from different types of cirrhosis.
The US Food and Drug Administration and the European Medicines Agency's Human Medicines Committee, after examining these studies, have approved Epclusa as an effective and safe drug for the fight against hepatitis.
Velpanat containing Sofosbuvir and Velpatasvir is one of the most effective combinations since these substances actively suppress the development of the virus. The positive effect of treatment is observed due to the fact that the causative agent of the disease ceases to multiply in the body.
Indications for use:
The drug "Epclusa" is prescribed for the diagnosis of any genotype of hepatitis C, including in the presence of concomitant cirrhosis. It can be used in the late stages of the development of the disease and in its course in a chronic form.
The package contains 28 white-coated tablets. Each contains 400 milligrams of Sofosbuvir and 100 milligrams of Velpatasvir. One pack is for monthly treatment.
Application and recommended dosage
During the therapeutic course, it is necessary to take one tablet every day at the same time. As a rule, the treatment lasts three months, but if at the end of this period the desired effect is not noticed, the duration of the course can be six months. To improve the results of therapy, the drug is used in combination with ribavirin.
Common side effects:
The appearance of post-treatment symptoms is noted by a very small number of patients. Also, as a rule, they do not have a pronounced character. Those taking the drug were dizzy, impaired attention, a slight memory impairment, shortness of breath, gastrointestinal tract disorders. Possible manifestation of side effects in the form of an allergic rash and spots on the skin. Among the post-treatment symptoms, there are anemia, lymphopenia, thrombocytopenia, leukopenia.
Velpanat is not intended for the treatment of hepatitis C in children and adolescents under the age of 18, pregnant or lactating women. Also, the use of the drug is not recommended for older people, patients with kidney disease. Contraindication is hypersensitivity to one of the active substances.
Interaction with other drugs
Velpatasvir and Sofosbuvir create a favorable environment in the body for the effects of P-ZT and BRCP preparations. Not recommended for use with inducers of P-glycoprotein. The use in parallel with agents that increase the pH of the stomach can lead to a decrease in the concentration of active substances.
It is necessary to use tablets before the expiration date (it is indicated on the package). The drug is stored in a dark place inaccessible to children at a temperature of 15 to 30 degrees Celsius. Also, avoid direct sunlight.
How to buy sofosbuvir and velpatasvir online?
You can order sofosbuvir velpatasvir buy online tablet 25% OFF and Free Shipping on Every Order... Per Bottel Velpanat 28Tab 210$ to 230$ in Indian Pharmacy Medixo Centre